SERPINB3 and cervical cancer: Accumulating evidence has validated that the variation in SCC antigen levels during the treatment could influence the prognosis of patients who experienced recurrence [35, 36] Li et al. have also shown that elevated pretreatment SCC antigen levels (> 3.5 ng/mL) were correlated to a higher risk of lymph node metastases and a poor response to NACT in cervical cancer patients who received NACT and underwent radical hysterectomy [37].